Find your next paid study

West Virginia UniversityNCT07317687

~$10 – $750

Observational

Randomized Feasibility Trial of Isocaloric Navy-Bean Substitution in Adults With MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

This study is a 24-week randomized crossover feasibility trial evaluating an isocaloric navy-bean dietary substitution in 40 adults with metabolic dysfunction-…

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Liver FibrosisMetabolic Dysfunction-Associated Steatohepatitis (MASH)

Icahn School of Medicine at Mount SinaiNCT07730853

Non-Alcoholic SteatohepatitisNon-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage …

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT03884075

~$10 – $5,625

Observational

A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs

This study will test two active evidence-based "practice coaching" (PC) interventions to improve opioid treatment programs' (OTPs') provision and sustained imp…

HIV/AIDSHepatitis CSubstance Use Disorders+1 more

Columbia UniversityNCT03135886

A Phase 2 Study of Emapalumab for Prevention of Liver Failure in Pediatric Indeterminate Severe Hepatitis Associated With T-Cell Activation: Severe Hepatitis Intervention With Emapalumab for Liver Disease

The goal of this study is to see whether a medicine called emapalumab, a monoclonal antibody, is safe and works well for patients aged 1 year and older who hav…

Hepatitis

Children's Healthcare of AtlantaNCT07744919

~$10 – $7,500

Phase 4

A Prospective Multicenter International Randomized Controlled Trial Comparing Surgical and Medical Therapies in the Treatment of Advanced Metabolic Dysfunction Associated Steatohepatitis

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health con…

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Non-Alcoholic Fatty Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis (MASH)+2 more

The Cleveland ClinicNCT06374875

Alcohol-associated Hepatitis

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol u…

CancerLiver CirrhosisChronic Hepatitis+4 more

~$10 – $7,500

Samer GawriehNCT07060638

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for th…

Helio GenomicsNCT05181826

~$10 – $1,125

Phase 1

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Two Doses of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunct…

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis

Regeneron PharmaceuticalsNCT06836609

~$10 – $8,750

Metabolic Dysfunction-Associated SteatohepatitisNon-alcoholic Fatty Liver Disease

A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabol…

GlaxoSmithKlineNCT06920043

~$10 – $7,500

Phase 4

Assessing Nutrition-aligned Resmetirom Roll-out

This randomized control trial aims to evaluate the effectiveness of combining resmetirom therapy (first approved pharmacological therapy for treating metabolic…

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

City University of New YorkNCT07680478

ObservationalRemote eligible

Feasibility Study of Time Restricted Eating and a Healthy Diet in Patients Receiving Liver-Directed Therapy for Hepatocellular Carcinoma

This is a feasibility study that will collect data to assess the potential effect of nutritional intervention. This prospective single-site trial will enroll a…

Liver Cancer, AdultMASH - Metabolic Dysfunction-Associated SteatohepatitisObesity and Overweight